Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Thank you for asking the question Ken, and even be

Message Board Public Reply | Private Reply | Keep | Replies (3)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154153
(Total Views: 2307)
Posted On: 05/18/2025 3:29:39 AM
Posted By: sjacobs26
Re: Katangolo #153150
Thank you for asking the question Ken, and even better was the response. Like Kant, I expect to see similar PD-L1 results across all cancers that over-express CCR5 due to the MOA. In the early Dr. Pestell days, they were targeting specific cancers due to the over-expression of CCR5. For TNBC, CCR5 was over-expressed in 95% of patients. I don’t recall what CRC was, but they are targeting it for a reason and it further supports potential AA due to limited treatment options and how ineffective ICIs are for MSS CRC.

Additionally, this brings Dr. Patterson’s statement to mind about how elegant of a molecule leronlimab is in the repolarization of macrophages and activating immune responses in so many different and deadly diseases. As ohm and now the company has shown, turning cold tumors hot due to PD-L1 increase is just another elegant benefit to this amazing molecule!

The challenge I see in getting this approved across so many different cancers quickly is getting the FDA to recognize the biomarkers such as CTC, CAML, and PD-L1 levels as surrogate endpoints instead of separate trails for each indication. I’m hopeful both Creatv MicroTech and the company are working with the FDA to get these biomarkers recognized and approved as surrogate endpoints, but not sure the extent of this process. Is Creatv MicroTech technology approved for these biomarkers or is a novel approach still in development? I’m patiently waiting for additional CRC trial sites to be added and enrollment to ramp up…and extremely optimistic where we are headed!


(23)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


Please do your own due diligence. All my posts and comments are not to be considered investment advice.




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us